EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+14.76%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$2.1B
AUM Growth
+$4.5M
(+0.21%)
Cap. Flow
-$189M
Cap. Flow
% of AUM
-9%
Top 10 Holdings %
Top 10 Hldgs %
51.83%
Holding
429
New
31
Increased
83
Reduced
267
Closed
35
Top Buys
| 1 |
abrdn Physical Gold Shares ETF
SGOL
|
$20M |
| 2 |
iShares Gold Trust
IAU
|
$19.8M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
$19.6M |
| 4 |
SPDR Gold Trust
GLD
|
$19.6M |
| 5 |
Invesco DB Oil Fund
DBO
|
$11M |
Top Sells
| 1 |
KE Holdings
BEKE
|
$70.4M |
| 2 |
Futu Holdings
FUTU
|
$37.4M |
| 3 |
Apple
AAPL
|
$18.8M |
| 4 |
Microsoft
MSFT
|
$13.6M |
| 5 |
Applied Materials
AMAT
|
$11.3M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Consumer Discretionary | 23.94% |
| 3 | Communication Services | 11.36% |
| 4 | Healthcare | 5.11% |
| 5 | Financials | 3.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Hologic
HOLX
$14.8B
| $303K | 0.01% |
4,646
-851
| -15% | -$55.5K |
|
302
BioCryst Pharmaceuticals
BCRX
$1.74B
| $301K | 0.01% |
33,592
+9,918
| +42% | +$88.9K |
|
303
Align Technology
ALGN
$9.76B
| $301K | 0.01% |
1,588
-366
| -19% | -$69.3K |
|
304
Solventum
SOLV
$12.5B
| $300K | 0.01% |
3,960
-431
| -10% | -$32.7K |
|
305
Revvity
RVTY
$9.95B
| $300K | 0.01% |
3,104
+108
| +4% | +$10.4K |
|
306
Henry Schein
HSIC
$8.22B
| $299K | 0.01% |
4,095
-501
| -11% | -$36.6K |
|
307
Cooper Companies
COO
$13.5B
| $298K | 0.01% |
4,186
-27
| -0.6% | -$1.92K |
|
308
Zimmer Biomet
ZBH
$20.8B
| $298K | 0.01% |
3,265
-29
| -0.9% | -$2.65K |
|
309
Credo Technology Group
CRDO
$23.2B
| $295K | 0.01% |
+3,185
| New | +$295K |
|
310
Baxter International
BAX
$12.1B
| $294K | 0.01% |
9,723
-148
| -1% | -$4.48K |
|
311
West Pharmaceutical
WST
$17.8B
| $294K | 0.01% |
1,343
-135
| -9% | -$29.5K |
|
312
Crinetics Pharmaceuticals
CRNX
$3.23B
| $291K | 0.01% |
10,131
+586
| +6% | +$16.9K |
|
313
ConocoPhillips
COP
$120B
| $290K | 0.01% |
3,232
-99
| -3% | -$8.88K |
|
314
Viatris
VTRS
$12B
| $288K | 0.01% |
32,239
-2,464
| -7% | -$22K |
|
315
Charles River Laboratories
CRL
$7.99B
| $284K | 0.01% |
1,874
+21
| +1% | +$3.19K |
|
316
DaVita
DVA
$9.69B
| $284K | 0.01% |
1,995
-155
| -7% | -$22.1K |
|
317
Bio-Techne
TECH
$8.23B
| $283K | 0.01% |
5,497
+235
| +4% | +$12.1K |
|
318
Sarepta Therapeutics
SRPT
$1.93B
| $283K | 0.01% |
16,525
+7,416
| +81% | +$127K |
|
319
Blackstone
BX
$133B
| $281K | 0.01% |
1,879
| – | – |
|
320
Robinhood
HOOD
$91.5B
| $281K | 0.01% |
+3,001
| New | +$281K |
|
321
Zebra Technologies
ZBRA
$15.8B
| $279K | 0.01% |
906
-155
| -15% | -$47.8K |
|
322
Chubb
CB
$112B
| $279K | 0.01% |
964
| – | – |
|
323
Apellis Pharmaceuticals
APLS
$3.62B
| $278K | 0.01% |
16,057
-778
| -5% | -$13.5K |
|
324
Marsh & McLennan
MMC
$101B
| $273K | 0.01% |
1,248
-15
| -1% | -$3.28K |
|
325
Intercontinental Exchange
ICE
$99.9B
| $265K | 0.01% |
1,447
-53
| -4% | -$9.72K |
|